Section Arrow
Quote
IGC.NYSE-M
- IGC Pharma
Quotes are at least 15-min delayed:2025/07/20 13:09 EDT
Regular Hours
Last
 0.359
+0.0199 (+5.87%)
Day High 
0.3639 
Prev. Close
0.3391 
1-M High
0.461 
Volume 
1.77M 
Bid
0.3313
Ask
0.3426
Day Low
0.3292 
Open
0.3406 
1-M Low
0.2974 
Market Cap 
28.45M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.35 
20-SMA 0.33 
50-SMA 0.32 
52-W High 0.495 
52-W Low 0.2525 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.09/-0.12
Enterprise Value
28.59M
Balance Sheet
Book Value Per Share
0.08
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.27M
Operating Revenue Per Share
0.01
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 13:09 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.